A hallmark of cancer cells is defects in the apoptotic cell death program. Apoptosis is a highly regulated cell suicide process that functions to remove unwanted cells. One means of inhibiting the apoptotic pathway in cancer cells is through up-regulation of the anti-apoptotic BCL-2 family members, including BCL-2, BCL-XL, and MCL-1. To restore the ability of cells to undergo apoptosis, small molecules have been designed to inhibit these proteins. However, determining how to predict patient response to these small molecules is still unknown.
To answer this question, the expression of multiple components of the BCL-2 family proteins was measured simultaneously in a multiplex format and correlated to response across panels of cell lines. This multiplex assay allows for accurate quantitation of protein levels. It is highly sensitive with wide dynamic range. This assay could also be used for studying drug response and is suitable for use in a high-throughput manner.
For Research Use Only. Not For Use In Diagnostic Procedures.
Lloyd Lam, Ph.D. is a Senior Scientist at AbbVie Inc, North Chicago. Dr. Lam has been in apoptosis research for 10 years. His primary interest is to define dependency of cancers to anti-apoptotic proteins and identify determinants of response to selective apoptosis compounds. Dr. Lam received his Ph.D. in Molecular and Cellular Pharmacology at University of Wisconsin-Madison and did his postdoc in Dr. Louis Staudt’s lab at NCI, NIH in Bethesda.
Reeti Maheshwari is a Research Scientist with >10 years’ experience in immunoassay development across different platforms in a variety of therapeutic areas. She also has >5 years’ experience as a clinical lab scientist. She holds a Master’s in Medical Biochemistry (GNDU, India), and another Master’s in Biotechnology from Illinois State University (Normal, IL).
Presented:Wed, February 28, 2018